Which procedure is performed before the administration of Y-90 therapy?

Which procedure is performed before the administration of Y-90 therapy?

• A. Whole body imaging with In-111 ibritumonab tiuxetan
• B. Chest X-ray
• C. CT scan of the abdomen
• D. Complete blood count (CBC)

Answer: (A)

The procedure that is performed before the administration of Y-90 therapy is whole body imaging with In-111 ibritumomab tiuxetan. This imaging is crucial as it provides important information about the distribution of lymphatic tissue and the extent of any malignancy, which aids in planning the treatment effectively. By visualizing the lymphatic system, healthcare providers can determine the precise areas that require therapy and assess the potential involvement of the disease, ultimately guiding the delivery of targeted radiation therapy with Y-90. In the context of Y-90 therapy, specifically for treating conditions like non-Hodgkin lymphoma, understanding the tumor burden prior to the treatment ensures that the procedure is both safe and effective. The imaging technique utilizes a radiolabeled monoclonal antibody that binds to the CD20 antigen prevalent on B-cell lymphomas, allowing for accurate mapping of lymphoid tissues. While the other listed procedures may provide valuable information or baseline data, they do not have the same direct role in the pre-treatment assessment for Y-90 therapy. For instance, a chest X-ray could evaluate thoracic structures but would not inform specifically about lymphoma distribution, whereas a CT scan of the abdomen might visualize potential metastases but lacks the specificity provided by the radiol

The procedure that is performed before the administration of Y-90 therapy is whole body imaging with In-111 ibritumomab tiuxetan. This imaging is crucial as it provides important information about the distribution of lymphatic tissue and the extent of any malignancy, which aids in planning the treatment effectively. By visualizing the lymphatic system, healthcare providers can determine the precise areas that require therapy and assess the potential involvement of the disease, ultimately guiding the delivery of targeted radiation therapy with Y-90.

In the context of Y-90 therapy, specifically for treating conditions like non-Hodgkin lymphoma, understanding the tumor burden prior to the treatment ensures that the procedure is both safe and effective. The imaging technique utilizes a radiolabeled monoclonal antibody that binds to the CD20 antigen prevalent on B-cell lymphomas, allowing for accurate mapping of lymphoid tissues.

While the other listed procedures may provide valuable information or baseline data, they do not have the same direct role in the pre-treatment assessment for Y-90 therapy. For instance, a chest X-ray could evaluate thoracic structures but would not inform specifically about lymphoma distribution, whereas a CT scan of the abdomen might visualize potential metastases but lacks the specificity provided by the radiol